Login / Signup

A clinical variable-based nomogram could predict the survival for advanced NSCLC patients receiving second-line atezolizumab.

Xiaoling ShangJianxiang ShiXiaohui WangChenglong ZhaoHaining YuHaiyong Wang
Published in: Cancer medicine (2021)
The clinical variable-based nomogram model could predict the survival benefit for NSCLC patients receiving second-line atezolizumab.
Keyphrases
  • small cell lung cancer
  • lymph node metastasis
  • advanced non small cell lung cancer
  • squamous cell carcinoma